Area of research
Hematology · Materials Chemistry
Research interest
Research interests include Multiple Myeloma Research and Treatments, Catalytic Processes in Materials Science, Language, Metaphor, and Cognition, and Nanoplatforms for cancer theranostics.
Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
Is the combination of Myelodysplastic syndromes and pulmonary fibrosis accidental or inevitable?
Negative effect of paraskeletal plasmacytoma on survival of patients with transplant-ineligible newly diagnosed multiple myeloma
High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation
Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study
Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic
Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study
Persistent fever-liver dysfunction-repeated bleeding-abnormal activation of natural killer cells
Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis
An integrated bioinformatical analysis of miR‑19a target genes in multiple myeloma
Mechanisms for T cell tolerance induced with granulocyte colony-stimulating factor
Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients
The Synthetic Compound Norcantharidin Induced Apoptosis in Mantle Cell Lymphoma In Vivo and In Vitro through the PI3K-Akt-NF-<i>κ</i>B Signaling Pathway
Expression levels of IL-27 and IL-17 in multiple myeloma patients: A higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival
[Norcantharidin induce anti-myeloma effect on nude mouse xenografts through NF-κB signal pathway].
Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts